Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/30/2025

Antibiotic Regimen for Cellulitis and Ear Infections

Pathogen Considerations

  • Cellulitis is primarily caused by beta-hemolytic streptococci and less commonly by Staphylococcus aureus, with ear infections commonly caused by Streptococcus species and Staphylococcus aureus 1, 2

First-Line Treatment Options

  • Clindamycin 300-450 mg orally three times daily for adults provides excellent coverage for both streptococci and staphylococci, making it ideal for concurrent cellulitis and ear infections 3
  • Vancomycin 15 mg/kg IV every 12 hours is recommended for patients with severe infection or MRSA risk factors 4, 5

Treatment Algorithm Based on Severity

  • For mild infection, oral clindamycin for 5-7 days is recommended 4, 3
  • For moderate infection, consider hospitalization with IV antibiotics initially, then transition to oral therapy once improving 4, 5
  • For severe infection, hospitalization with vancomycin plus either piperacillin-tazobactam or imipenem/meropenem is recommended 4, 5

Special Considerations

  • The Infectious Diseases Society of America recommends ensuring MRSA coverage with clindamycin, trimethoprim-sulfamethoxazole, doxycycline, or vancomycin for patients with MRSA risk factors 1, 6
  • The American College of Clinical Pharmacy suggests that 5 days is typically sufficient for uncomplicated infections, but treatment should be extended if infection has not improved within this time period 4

Adjunctive Measures

  • Elevation of affected area if cellulitis involves an extremity is recommended 4, 7
  • Treatment of predisposing factors, such as tinea pedis or venous eczema, is also recommended 5, 7

Common Pitfalls to Avoid

  • Failing to examine interdigital toe spaces in lower-extremity cellulitis can lead to inadequate treatment 4, 5
  • Unnecessarily broad antibiotic coverage for typical cellulitis should be avoided, as streptococcal coverage is usually sufficient 1, 6
  • Inadequate duration of therapy or failure to reassess after 5 days can lead to treatment failure 4
  • Not considering MRSA coverage when risk factors are present can also lead to treatment failure 3, 1